Compare Citius Pharmaceuticals Inc (CTXR) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Workiva Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Workiva Inc trades at $67.9 (market cap $3.76B). The key difference: Workiva Inc is far larger — about 187.9× Citius Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | WK | |
|---|---|---|
Market Cap | $20.01M | $3.76B |
Sector | Health | Technology |
52-Week High | $1.82 | $93.31 |
52-Week Low | $0.48 | $44.31 |
Enterprise Value | $16.23M | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.
The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.
WK trades at $67.73, up 0.61% today, near its consensus price target of $69. The stock shows bullish technical signals with strong moving average support and recent earnings beats. Revenue grew to $966 million in 2026 with net income turning positive at $47 million, reflecting improved profitability. Positive sentiment is driven by AI product launches and consistent earnings outperformance.
Outlook remains positive given earnings momentum and AI innovation, but high valuation multiples pose risks. Investors face elevated P/E and EV/EBITDA ratios, requiring sustained growth to justify premiums. Competitive pressures and execution on AI initiatives are key to maintaining upward trajectory amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
